Alzheimer's disease and resveratrol
A clinical study has shown the association of resveratrol with Alzheimer's markers
Copper news based on the materials of Science Daily: Resveratrol impacts Alzheimer's disease biomarkerThe largest clinical study of resveratrol in high dosage on subjects with Alzheimer's disease (with moderate and moderate dementia) showed stabilization of the biomarker, which usually decreases with the progression of the disease.
Resveratrol is a natural antioxidant found, for example, in red grapes, raspberries, dark chocolate and some red wines. The authors call the results of his trial "very interesting", although they do not consider them the basis for recommendations on taking resveratrol.
The results of the study, which took place at 21 medical centers in the United States, are published in the journal Neurology. This is a randomized placebo-controlled double-blind trial (phase II), for which synthetic resveratrol was used, which is not sold in this form and dosage. 119 people participated in the tests. The highest dosage (it was progressively increased) is 1 g orally twice a day. In terms of resveratrol content, this is the equivalent of about 1,000 bottles of red wine. The study lasted 12 months.
The experimental group receiving the active substance showed only small changes in the level of amyloid-beta-40 (Abeta-40) in the blood and cerebrospinal fluid. In the control group taking placebo, the level of Abet-40 decreased during the study.
Changes in concentrations of beta-amyloid-40 (ng/l) in cerebrospinal fluid (A) and blood plasma (B). The mean values and confidence interval in subjects treated with resveratrol are red lines, in the control group – green. Graph from the article by Turner et al. A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer's disease, published in open access in the journal Neurology – VM."A drop in Abet-40 is observed with the aggravation of dementia and the progression of Alzheimer's disease, but we still cannot conclude that the effect of resveratrol is positive," says one of the authors Scott Turner from Georgetown University.
Resveratrol was chosen because it activates sirtuin proteins that are activated when caloric intake is restricted (there are a number of animal studies showing that prolonged caloric restriction to 2/3 of the norm prevents or delays age-related diseases, including Alzheimer's).
The study also showed that resveratrol in high dosage is safe and well tolerated by patients. Those who took resveratrol also lost weight during the trials. The placebo group, on the contrary, gained weight.
One of the results, however, turned out to be embarrassing: patients from the experimental group lost some brain volume. The researchers' working hypothesis is that this is a consequence of a decrease in inflammation and edema.
A larger phase three study is expected to be conducted, during which the effectiveness of resveratrol will be determined.
Portal "Eternal youth" http://vechnayamolodost.ru
16.09.2015